sight sciences, inc. is a medical devices company based out of menlo park, california, united states.
Company profile
Ticker
SGHT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Sight Sciences UK, Ltd. • Sight Sciences GmbH ...
IRS number
800625749
SGHT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
12 Mar 24
8-K
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
7 Mar 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
23 Jan 24
8-K
Entry into a Material Definitive Agreement
18 Dec 23
8-K
Other Events
7 Dec 23
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Sight Sciences Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Regulation FD Disclosure
26 Oct 23
Transcripts
SGHT
Earnings call transcript
2023 Q4
7 Mar 24
SGHT
Earnings call transcript
2023 Q3
7 Nov 23
SGHT
Earnings call transcript
2023 Q2
3 Aug 23
SGHT
Earnings call transcript
2023 Q1
4 May 23
SGHT
Earnings call transcript
2022 Q4
13 Mar 23
SGHT
Earnings call transcript
2022 Q3
13 Nov 22
SGHT
Earnings call transcript
2022 Q2
12 Aug 22
SGHT
Earnings call transcript
2022 Q1
14 May 22
SGHT
Earnings call transcript
2021 Q4
25 Mar 22
SGHT
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
4
JEREMY B. HAYDEN
4 Apr 24
4
Paul Badawi
4 Apr 24
4
David Badawi
4 Apr 24
4
Sam Boong Park
4 Apr 24
4
Alison Bauerlein
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 144.50 mm | 144.50 mm | 144.50 mm | 144.50 mm | 144.50 mm | 144.50 mm |
Cash burn (monthly) | 3.34 mm | 4.61 mm | 4.47 mm | 5.27 mm | 3.28 mm | 4.68 mm |
Cash used (since last report) | 22.89 mm | 31.61 mm | 30.65 mm | 36.12 mm | 22.46 mm | 32.11 mm |
Cash remaining | 121.61 mm | 112.89 mm | 113.85 mm | 108.38 mm | 122.04 mm | 112.39 mm |
Runway (months of cash) | 36.4 | 24.5 | 25.5 | 20.6 | 37.3 | 24.0 |
Institutional ownership, Q3 2023
55.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 4 |
Closed positions | 12 |
Increased positions | 24 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 78.31 bn |
Total shares | 27.57 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
D1 Capital Partners | 5.85 mm | $19.72 bn |
KCK | 4.65 mm | $15.66 bn |
Staffan Encrantz | 4.02 mm | $34.95 mm |
BLK Blackrock | 1.65 mm | $5.55 bn |
Jackson Square Partners | 1.46 mm | $4.90 bn |
Vanguard | 1.41 mm | $4.75 bn |
Russell Investments | 1.06 mm | $3.59 bn |
JPM JPMorgan Chase & Co. | 1.05 mm | $3.53 bn |
ArrowMark Colorado | 714.81 k | $2.41 bn |
Apollo Management | 671.52 k | $2.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Alison Bauerlein | Common Stock | Sell | Dispose S | No | No | 5.079 | 10,123 | 51.41 k | 426,248 |
3 Apr 24 | Sam Boong Park | Common Stock | Sell | Dispose S | No | No | 5.079 | 3,414 | 17.34 k | 261,754 |
3 Apr 24 | David Badawi | Common Stock | Sell | Dispose S | No | No | 5.079 | 3,128 | 15.89 k | 1,762,776 |
3 Apr 24 | Paul Badawi | Common Stock | Sell | Dispose S | No | No | 5.079 | 12,571 | 63.85 k | 5,750,729 |
3 Apr 24 | Jeremy B. Hayden | Common Stock | Sell | Dispose S | No | No | 5.079 | 4,893 | 24.85 k | 168,620 |
News
Sight Sciences Announces The Publication Of Large-Scale, Real-World MIGS Study Demonstrating The Aqueous Outflow Restorative Procedure With OMNI Surgical System Technology Is Effective At Lowering Both IOP And IOP Reducing Medications At 2 Years In Patients With Glaucoma
10 Apr 24
Needham Reiterates Hold on Sight Sciences
10 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 Apr 24
Sight Sciences Announces The Results Of The 3-Year Prospective GEMINI Trial And The Cross-Over Phase Of The SAHARA RCT At The 2024 American Society Of Cataract And Refractive Surgery Annual Meeting
2 Apr 24
Stifel Maintains Buy on Sight Sciences, Raises Price Target to $7
8 Mar 24
Press releases
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
10 Apr 24
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
2 Apr 24
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
26 Mar 24
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
7 Mar 24
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
14 Feb 24